All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
| dc.rights.license | open | en_US |
| dc.contributor.author | REQUENA, Maria-Bernarda | |
| dc.contributor.author | PROTOPOPESCU, Camelia | |
| dc.contributor.author | STEWART, Ashleigh C | |
| dc.contributor.author | VAN SANTEN, Daniela K | |
| dc.contributor.author | KLEIN, Marina B | |
| dc.contributor.author | JARRIN, Inmaculada | |
| dc.contributor.author | BERENGUER, Juan | |
| hal.structure.identifier | Statistics In System biology and Translational Medicine [SISTM] | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | WITTKOP, Linda | |
| dc.contributor.author | SALMON, Dominique | |
| dc.contributor.author | RAUCH, Andri | |
| dc.contributor.author | PRINS, Maria | |
| dc.contributor.author | VAN DER VALK, Marc | |
| dc.contributor.author | SACKS-DAVIS, Rachel | |
| dc.contributor.author | HELLARD, Margaret E | |
| dc.contributor.author | CARRIERI, Patrizia | |
| dc.contributor.author | LACOMBE, Karine | |
| dc.date.accessioned | 2024-02-20T10:14:46Z | |
| dc.date.available | 2024-02-20T10:14:46Z | |
| dc.date.issued | 2024-01-06 | |
| dc.identifier.issn | 1873-4758 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/188251 | |
| dc.description.abstractEn | BACKGROUND: Among people living with HIV and hepatitis C virus (HCV), people who inject drugs (PWID) have historically experienced higher mortality rates. Direct-acting antivirals (DAA), which have led to a 90 % HCV cure rate independently of HIV co-infection, have improved mortality rates. However, DAA era mortality trends among PWID with HIV/HCV remain unknown. Using data from the International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC), we compared pre/post-DAA availability mortality changes in three groups: PWID, men who have sex with men (MSM), and all other participants. METHODS: We included InCHEHC participants with HIV/HCV followed between 2010 and 2019 in Canada, France, the Netherlands, Spain, and Switzerland. All-cause mortality hazard was compared in the three groups, using Cox proportional hazards regression models adjusted for sex, age, advanced fibrosis/cirrhosis, and pre/post DAA availability. RESULTS: Of the 11,029 participants, 76 % were men, 46 % were PWID, baseline median age was 46 years (interquartile range [IQR] = 40;51), and median CD4 T-cell count was 490 cells/mm(3) (IQR = 327;689). Over the study period (median follow-up = 7.2 years (IQR = 3.7;10.0)), 6143 (56 %) participants received HCV treatment, 4880 (44 %) were cured, and 1322 participants died (mortality rate = 1.81/100 person-years (PY) [95 % confidence interval (CI)=1.72-1.91]). Overall, PWID had higher mortality rates than MSM (2.5/100 PY [95 % CI = 2.3-2.6] vs. 0.8/100 PY [95 % CI = 0.7-0.9], respectively). Unlike women with other transmission modes, those who injected drugs had a higher mortality hazard than men who did not inject drugs and men who were not MSM (adjusted Hazard-Ratio (aHR) [95 % CI] = 1.3[1.0-1.6]). Post-DAA availability, mortality decreased among MSM in the Netherlands, Spain, and Switzerland and increased among PWID in Canada (aHR [95 % CI] = 1.73 [1.15-2.61]). CONCLUSION: Post-DAA availability, all-cause mortality did not decrease in PWID. Determinants of cause-specific deaths (drug-related, HIV-related, or HCV-related) need to be identified to explain persistently high mortality among PWID in the DAA era. | |
| dc.language.iso | EN | en_US |
| dc.subject.en | Direct-acting antivirals | |
| dc.subject.en | HIV | |
| dc.subject.en | Hepatitis C virus | |
| dc.subject.en | Mortality | |
| dc.subject.en | People who inject drugs | |
| dc.title.en | All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019 | |
| dc.title.alternative | Int J Drug Policy | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.drugpo.2023.104311 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38184902 | en_US |
| bordeaux.journal | International Journal of Drug Policy | en_US |
| bordeaux.page | 104311 | en_US |
| bordeaux.volume | 124 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.institution | INRIA | en_US |
| bordeaux.team | SISTM_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04467710 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-02-20T10:14:49Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=International%20Journal%20of%20Drug%20Policy&rft.date=2024-01-06&rft.volume=124&rft.spage=104311&rft.epage=104311&rft.eissn=1873-4758&rft.issn=1873-4758&rft.au=REQUENA,%20Maria-Bernarda&PROTOPOPESCU,%20Camelia&STEWART,%20Ashleigh%20C&VAN%20SANTEN,%20Daniela%20K&KLEIN,%20Marina%20B&rft.genre=article |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||